© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
NAFLD is the leading indicator of mortality among Medicare beneficiaries with hepatocellular carcinoma.
The combination improved both overall survival and patient-reported outcomes.
The regulatory agency requested further data to show whether its benefits outweigh its risks.
This new test could “play an important role” in screening people who are at risk for developing hepatocellular carcinoma.
A third of patients treated with Opdivo plus Yervoy experienced complete or partial tumor remission.
New research shows that treating these viruses can reduce liver cancer risk.
Available vaccines offer protection against cervical, anal, oral, liver and stomach cancers.
Efficacy of the combination was investigated in a multicenter, multiple cohort, open-label trial conducted in patients with HCC.
A triple regimen of Opdivo, Yervoy and Cabometyx showed good antitumor activity, but severe side effects were common.
Transplants due to hepatitis C have dropped dramatically, especially among people with liver cancer.
Those with NAFLD or NASH and cirrhosis should undergo regular screening.
Tecentriq plus Avastin improved both overall survival and patient-reported outcomes.
The LIVER Act would increase funding for liver cancer and hepatitis B research and prevention.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
